# Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema

> **NCT05217680** · PHASE3 · COMPLETED · sponsor: **Laboratorios Sophia S.A de C.V.** · enrollment: 510 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **BIOLOGICAL:** Lucentis®

## Key facts

- **NCT ID:** NCT05217680
- **Lead sponsor:** Laboratorios Sophia S.A de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-24
- **Primary completion:** 2025-08-18
- **Final completion:** 2025-11-25
- **Target enrollment:** 510 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05217680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05217680, "Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05217680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*